Early impairment of coronary flow reserve is not associated with Chlamydia pneumoniae antibodies

Annals of Medicine

Volumn 34, Issue 4, 2002, Pages 284-290

  Janatuinen, Tuula ^a   Friberg, Johan ^a   Viljanen, Matti K ^a   Raitakari, Olli T ^a   Nuutila, Pirjo ^a   Vainionpää, Raija ^a   Oksi, Jarmo ^a   Peltonen, Reijo ^a   Engblom, Erik ^a   Laine, Hanna ^a   Knuuti, Juhani ^a  

^a TURKU PET CENTRE   (Finland)

Author keywords

Blood flow; Chlamydia pneumoniae; Positron emission tomography

Indexed keywords

APOLIPOPROTEIN A; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; ATHEROSCLEROSIS; BLOOD CHEMISTRY; BODY MASS; CARDIOVASCULAR RISK; CHLAMYDOPHILA PNEUMONIAE; CORONARY ARTERY BLOOD FLOW; DIASTOLIC BLOOD PRESSURE; HEART MUSCLE BLOOD FLOW; HUMAN; HUMAN EXPERIMENT; HYPEREMIA; ISCHEMIC HEART DISEASE; MALE; NORMAL HUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REST; STATISTICAL ANALYSIS;

ADULT; ANTIBODIES, BACTERIAL; BIOLOGICAL MARKERS; CHLAMYDOPHILA INFECTIONS; CHLAMYDOPHILA PNEUMONIAE; CORONARY ARTERIOSCLEROSIS; CORONARY CIRCULATION; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MALE; RISK FACTORS;

EID: 18544368843     PISSN: 07853890     EISSN: None     Source Type: Journal    
DOI: 10.1080/078538902320322547     Document Type: Article

References (42)

1. Ross R. Atherosclerosis - An Inflammatory Disease. N Engl J Med 1999; 340: 115-26.
2. Schwartz SM, Murry CE. Proliferation and the monoclonal origins of atherosclerotic lesions. Annu Rev Med 1998; 49: 437-60.
3. Wick G, Romen M, Amberger A, Metzler B, Mayr M, Falkensammer G, et al. Atherosclerosis, autoimmunity, and vascular-associated lymphoid tissue. FASEB J 1997; 11: 1199-207.
4. Danesh J, Collins R, Peto R. Chronic infections and coronary heart disease: is there a link? Lancet 1997; 350: 430-6.
5. Kuo CC, Shor A, Campell LA, Fukushi H, Patton DL, Grayston JT. Demonstration of Chlamydia pneumoniae in atherosclerotic lesions of coronary arteries. J Infect Dis 1993; 167: 841-9.
6. Fong IW, Chiu B, Viira E, Fong MW, Jang D, Mahony J. Rabbit model for Chlamydia pneumoniae infection. J Clin Microbiol 1997; 35: 48-52.
7. Gupta S, Leathman EW, Carrington D, Mendall MA, Kaski JC, Camm AJ. Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azitromycin in male survivors of myocardial infarction. Circulation 1997; 96: 404-7.
8. Gurfinkel E, Bozovich G, Beck E, Testa E, Livellara B, Mautner B, for the ROXIS Study Group. Treatment with the antibiotic roxithromycin in patients with acute non-Q-wave coronary syndromes: The final report of the ROXIS study. Eur Heart J 1999; 20: 121-7.
9. Lupi A, Buffon A, Finocchario ML, Conti E, Maseri A, Crea F. Mechanisms of adenosine-induced epicardial coronary artery dilatation. Eur Heart J 1997; 18: 614-7.
10. Smits P, Williams SB, Lipson DE, Banitt P, Rongen GA, Creager MA. Endothelial release of nitric oxide contributes to the vasodilator effect of adenosine in humans. Circulation 1995; 92: 2135-41.
11. Davis CA 3rd, Sherman AJ, Yaroshenko Y, Harris KR, Hedjbeli S, Parker MA, et al. Coronary vascular responsiveness to adenosine is impaired additively by blockage of nitric oxide synthesis and a sulfonylurea. J Am Coll Cardiol 1998; 31: 816-22.
12. Buus NH, Bottcher M, Hermansen F, Sander M, Nielsen TT, Mulvany MJ. Influence of nitric oxide synthase and adrenergic inhibition on adenosine-reduced myocardial hyperemia. Circulation 2001; 104: 2305-10.
13. Clark JC, Crouzel C, Meyer GJ, Strijckmans K. Current methodology for oxygen-15 production for clinical use. Int J Rad Appl Instrum 1987; 38: 597-600.
14. Crouzel C, Clark J, Brihaye C, Långström O, Lemaire C, Meyer G, et al. Radiochemistry automation for PET. In: Stöckling G, Pike V, eds. Radiopharmaceuticals for Positron Emission Tomograpby. The Netherlands: Kluwer Academic Publishers; 1993: 45-90.
15. Iida H, Rhodes C, de Silva R, Araujo LI, Bloomfield PM, Lammertsma AA, et al. Use of the left ventricular time-activity curve as a noninvasive input function in dynamic oxygen-15-water positron emission tomography. J Nucl Med 1992; 33: 1669-77.
16. 15O and dynamic positron emission tomography: strategy for quantification in relation to the partial-volume effect. Circulation 1988; 78: 104-15.
17. Iida H, Takahashi A, Tamura Y, Ono Y, Lammertsma A. Myocardial blood flow: comparison of oxygen-15-water bolus injection, slow infusion and oxygen-15-carbon dioxide inhalation. J Nucl Med 1995; 36: 78-85.
18. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
19. Leinonen M, Saikku P. Infections and atherosclerosis. Scand Cardiovasc J 1999; 34: 12-20.
20. Anderson JL, Muhlestein JB, Carlquist J, Allen A, Trehan S, Nielson C, et al. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection: the Azithromycin in Coronary Artery Disease: Elimination of Myocardial Infarction with Chlamydia (ACADEMIC) Study. Circulation 1999; 99: 1540-7.
21. Sinisalo J, Mattila K, Nieminen MS, Valtonen V, Syrjälä M, Sundberg S, et al. The effect of prolonged doxycycline therapy on Chlamydia pneumoniae serological markers, coronary heart disease risk factors and forearm basal nitric oxide production. J Antimicrob Chemother 1998; 41: 85-92.
22. Liuba P, Karnani P, Pesonen E, Paakkari I, Forslid A, Johansson L, et al. Endothelial dysfunction after repeated Chlamydia pneumoniae infection in apolipoprotein E-knockout mice. Circulation 2000; 102: 1039-44.
23. Muhlestein JB, Anderson JL, Hammond EH, Zhao L, Trehan S, Schwobe EP, et al. Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model. Circulation 1998; 97: 633-6.
24. Melnick SL, Shahar E, Folsom AR, Grayston JT, Sorlie PD, Wang S-P, et al., for the Atherosclerosis Risk in Communities (ARIC) Study Investigators. Past infection by Chlamydia pneumoniae strain TWAR and asymptomatic carotid atherosclerosis. Am J Med 1993; 95: 499-504.
25. Schmidt C, Hulthe J, Wikstrand, Gnarpe H, Gnarpe J, Agewall S, et al. Chlamydia pneumoniae seropositivity is associated with carotid artery intima-media thickness. Stroke 2000; 31: 1526-31.
26. Espinola-Klein C, Rupprecht H-J, Blankenberg S, Bickel C, Kopp H, Rippin G, et al. Are morphological or functional changes in the carotid artery wall associated with Chlamydia pneumoniae, Helicibacter pylori, Cytomegalovirus, or Herpes Simplex virus infection? Stroke 2000; 31: 2127-33.
27. Markus HS, Sitzer M, Carrington D, Mendall MA, Steinmetz H. Chlamydia pneumoniae infection and early asymptomatic carotid atherosclerosis. Circulation 1999; 100: 832-7.
28. Pitkänen OP, Raitakari OT, Niinikoski H, Nuutila P, Iida H, Voipio-Pulkki L-M, et al. Coronary flow reserve is impaired in young men with familial hypercholesterolemia. J Am Coll Cardiol 1996; 28: 1705-11.
29. Pitkänen OP, Nuutila P, Raitakari OT, Porkka K, Iida H, Nuotio I, et al. Coronary flow reserve in young men with familial combined hyperlipidemia. Circulation 1999; 99: 1678-84.
30. Pitkänen OP, Nuutila P, Raitakari OT, Rönnemaa T, Koskinen P, Iida H, et al. Coronary flow reserve is reduced in young men with IDDM. Diabetes 1998; 47: 248-54.
31. Laine H, Raitakari OT, Niinikoski H, Pitkänen OP, Iida H, Viikari J, et al. Early impairment of coronary flow reserve in young men with borderline hypertension. J Am Coll Cardiol 1998; 32: 147-53.
32. Raitakari OT, Pitkänen O-P, Lehtimäki T, Lahdenperä S, Iida H, Ylä-Herttuala S, et al. In vivo low density lipoprotein oxidation relates to coronary reactivity in young men. J Am Coll Cardiol 1997; 30: 97-102.
33. Gould KL, Martucci JP, Goldberg DI, Hess MJ, Edens RP, Latifi R, et al. Short-term cholesterol lowering decreases size and severity of perfusion abnormalities by positron emission tomography after dipyridamole in patients with coronary artery disease. A potential non-invasive marker of healing coronary endothelium. Circulation 1994; 89: 1530-8.
34. Janatuinen T, Laaksonen R, Vesalainen R, Raitakari O, Lehtimäki T, Nuutila P, et al. Effect of lipid-lowering therapy with pravastatin on myocardial blood flow in young mildly hypercholesterolemic adults. J Cardiovasc Pharmacol 2001; 38: 561-8.
35. Kaufmann PA, Gnecchi-Ruscone T, di Terlizzi M, Schäfers KP, Lüscher TF, Camici PG. Coronary heart disease in smokers. Vitamin C restores coronary microcirculatory function. Circulation 2000; 102: 1233-8.
36. Raitakari OT, Toikka JO, Laine H, Ahotupa M, Iida H, Viikari JSA, et al. Reduced myocardial flow reserve relates to increased carotid intima-media thickness in healthy young men. Atherosclerosis 2001; 156: 469-75.
37. Tuuminen T, Varjo S, Ingman H, Weber T, Oksi J, Viljanen M. The prevalence of Chlamydia pneumoniae and Mycoplasma pneumoniae IgG and IgA antibodies in a healthy Finnish population as analyzed by quantitative enzyme immunoassays (EIAs). Clin Diagn Lab Immunol 2000; 7: 734-8.
38. Campell LA, Kuo C-C, Wang S-P, Grayston T. Serological response to Chlamydia pneumoniae infection. J Clin Microbiol 1990; 28: 1261-4.
39. Uren NG, Melin JA, De Bruyne B, Wijns W, Baudhuin T, Camici PG. Relation between myocardial blood flow and the severity of coronary artery stenosis. N Engl J Med 1994; 330: 1782-8.
40. Uren NG, Camici PG, Melin JA, Bol A, de Bruyne B, Radvan J et al. Effect of aging on myocardial perfusion reserve. J Nucl Med 1995; 36: 2032-6.
41. Chareonthaitawee P, Kaufmann PA, Rimoldi O, Camici PG. Heterogeneity of resting and hyperemic myocardial blood flow in healthy humans. Cardiovasc Res 2001; 50: 151-61.
42. Chan SY, Brunken RC, Czernin, Porenta G, Kuhle W, Krivokapich J et al. Comparison of maximal myocardial blood flow during adenosine infusion with that of intravenous dipyridamole in normal men. J Am Coll Cardiol 1992; 20: 979-85.